The last age group of the population unable to get a Covid-19 vaccine may soon be able to do so – and much earlier than anticipated.
Pfizer-BioNTech is expected to file a submission for emergency use to the Food and Drug Administration for a vaccine regimen designed for use in children aged six months to five years, according to a person familiar with the plan. The companies could file for the authorization as early as Tuesday.
Clinical trials last fall showed that the low doses of the vaccine generated protection in children up to 2 years old but failed to do so in kids aged 2-5. The companies announced in December they’d add a third dose to its trials, which would delay the submission to the FDA.
Read this story now for free
To continue reading, sign up for our newsletter and get unlimited access to WABE.org
You can select your preferences for news and local content. We will never share your email address. Learn how your newsletter sign-up will support WABE and Public Media
